Diabetic Nephropathy
📧 Sign up to get email alerts when something new happens for Diabetic Nephropathy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2013-06-11FDA Approved: LOSARTAN POTASSIUM — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for Losartan Potassium submitted by Aurobindo Pharma Limited.
-
FDA approval · 2013-06-10FDA Approved: LOSARTAN POTASSIUM — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved a supplemental application for losartan potassium by Alembic Pharmaceuticals Limited.
-
CLINICAL_TRIALS trial_result · 2013-06-06Clinical Trial Update: Serum 1,25-dihydroxyvitamin D Levels in Type 2 Diabetes Mellitus Patients With Different Levels of Albuminuria
This completed clinical trial examined serum 1,25-dihydroxyvitamin D levels in patients with type 2 diabetes and varying levels of albuminur…
-
CLINICAL_TRIALS trial_result · 2013-05-31Clinical Trial Update: Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN) [Phase 4]
Phase 4 clinical trial evaluating adrenocorticotropic hormone (ACTH) for nephrotic-range proteinuria in patients with diabetic nephropathy; …
-
CLINICAL_TRIALS trial_result · 2013-05-08Clinical Trial Update: A Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy [Phase 4]
A Phase 4 clinical study evaluating the efficacy and safety of combining cilostazol and probucol in patients with diabetic nephropathy has c…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2013-04-23Clinical Trial Update: Limb Ischemic Preconditioning for Prevention of Contrast Media Induced Nephropathy in Diabetic Kidney Patient [NA]
A clinical trial update on limb ischemic preconditioning to prevent contrast-induced nephropathy in patients with diabetic kidney disease; t…
-
CLINICAL_TRIALS trial_result · 2013-03-14Clinical Trial Update: Sex-specific Association With Kidney Disease
A completed clinical trial studying sex-specific associations with kidney disease in diabetic nephropathy. The sponsor listed is University …
-
FDA approval · 2013-03-11FDA Approved: IRBESARTAN — Supplemental Application (NorthStar RxLLC)
FDA approved a supplemental application for IRBESARTAN submitted by NorthStar RxLLC under an ANDA. The approval pertains to the supplemental…
-
FDA approval · 2013-01-28FDA Approved: LOSARTAN POTASSIUM — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approves a supplemental application for Losartan Potassium from Macleods Pharmaceuticals Limited (ANDA202230), authorizing the generic p…
-
CLINICAL_TRIALS trial_result · 2013-01-16Clinical Trial Update: SLC2A1 Variants and Diabetic Nephropathy
A completed clinical trial from University of Sao Paulo General Hospital studied SLC2A1 gene variants in relation to diabetic nephropathy.
-
CLINICAL_TRIALS trial_result · 2013-01-04Clinical Trial Update: Colchicine for Diabetic Nephropathy [Phase 2]
Phase 2 clinical trial investigating colchicine for diabetic nephropathy; current status is unknown.
-
FDA approval · 2012-12-20FDA Approved: LOSARTAN POTASSIUM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Losartan Potassium from Aurobindo Pharma Limited, resulting in approval of a generic losartan po…
-
FDA approval · 2012-12-19FDA Approved: LOSARTAN POTASSIUM — Supplemental Application (Quallent Pharmaceuticals Health LLC)
FDA approved a supplemental application for Losartan Potassium submitted by Quallent Pharmaceuticals Health LLC.
-
FDA approval · 2012-12-19FDA Approved: LOSARTAN POTASSIUM 25 MG — Supplemental Application (Strides Pharma Science Limited)
FDA approved the supplemental application for Losartan Potassium 25 mg by Strides Pharma Science Limited, authorizing the generic product fo…
-
FDA approval · 2012-12-19FDA Approved: LOSARTAN POTASSIUM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA has approved Lupin Pharmaceuticals' supplemental application for Losartan Potassium, a generic product, via ANDA indicating an additiona…
-
CLINICAL_TRIALS withdrawal · 2012-12-17Clinical Trial Update: Flavonoids in the Treatment of Endothelial Dysfunction in Children With Diabetes [NA]
A clinical trial evaluating flavonoids for endothelial dysfunction in children with diabetes has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2012-12-06Clinical Trial Update: Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy [Phase 4]
This is a Phase 4 clinical trial evaluating the effects of ramipril and clopidogrel on oxidative stress, vascular inflammation, and endothel…
-
CLINICAL_TRIALS trial_result · 2012-11-30Clinical Trial Update: Effect of Calcium Channel Blocker on the Serum Fibrobalst Growth Factor-23 (FGF-23) Levels in Type-2 Diabetic Patients With Proteinuria Purpose [Phase 4]
Phase 4 study assessing whether the calcium channel blocker amlodipine influences serum FGF-23 levels and other clinical/laboratory paramete…
-
CLINICAL_TRIALS withdrawal · 2012-11-16Clinical Trial Update: Adalat XL vs Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients [Phase 3]
A Phase 3 trial comparing Adalat XL to Diltiazem in hypertensive patients with diabetic nephropathy has been withdrawn.
-
FDA approval · 2012-11-14FDA Approved: IRBESARTAN — Original Application (Chartwell RX, LLC)
The FDA approved Chartwell RX, LLC's original Abbreviated New Drug Application for irbesartan, enabling a generic version of the medication.
-
CLINICAL_TRIALS trial_result · 2012-11-12Clinical Trial Update: Prevention of Renal Complications of Diabetes With Thiamine [Phase 4]
This ClinicalTrials.gov update reports on a Phase 4 trial evaluating thiamine to prevent renal complications in diabetic nephropathy. The cu…
-
FDA approval · 2012-10-15FDA Approved: IRBESARTAN — Original Application (Alembic Pharmaceuticals Limited)
FDA approved Alembic Pharmaceuticals Limited's original ANDA for irbesartan, a generic angiotensin II receptor blocker for hypertension and …
-
CLINICAL_TRIALS trial_result · 2012-10-10Clinical Trial Update: FGF-23 and Endothelial Dysfunction in Diabetic Proteinuric Patients [Phase 4]
A Phase 4 trial examining the relationship between FGF-23 and endothelial dysfunction in diabetic patients with proteinuria has completed.
-
FDA approval · 2012-10-03FDA Approved: IRBESARTAN — Original Application (NorthStar RxLLC)
FDA approves the original ANDA for irbesartan (IRBESARTAN) from NorthStar RxLLC as a generic version of the hypertension medicine.
-
FDA approval · 2012-09-28FDA Approved: COZAAR — Supplemental Application (Organon LLC)
FDA approved a supplemental application for Cozaar (losartan potassium) filed by Organon LLC.